Home
Drugs
Topical corticosteroids

Topical corticosteroids

Drug

Related News

Amlitelimab Meets Primary Endpoints in Phase 3 Atopic Dermatitis Trials

Apr 02, 2026

Phase 3 trial results show amlitelimab met primary endpoints in two monotherapy studies for moderate-to-severe atopic dermatitis, with combination therapy demonstrating the strongest efficacy. The investigational OX40L-targeting antibody showed comparable efficacy between every-4-week and every-12-week dosing intervals. Safety data revealed two cases of Kaposi sarcoma in patients with known risk factors among 4,630 exposed patients.

Lebrikizumab and Stapokibart Show Efficacy in Pediatric Atopic Dermatitis Trials

Mar 16, 2026

Two phase 3 trials demonstrate significant improvements in skin clearance and disease severity for children and adolescents with moderate-to-severe atopic dermatitis treated with targeted biologics.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT06241118	A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor	RECRUITING	PHASE3
NCT06224348	A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids	COMPLETED	PHASE3
NCT05492578	Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials	ENROLLING_BY_INVITATION	PHASE2/PHASE3
NCT04878770	NMF-CsA-Dupi Trial	UNKNOWN	NA
NCT03461302	Efficacy of Topical Coal Tar in Children With Atopic Dermatitis	UNKNOWN	PHASE4
NCT00120523	5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis	COMPLETED	PHASE3